Most people with Hutchinson-Gilford progeria syndrome (HGPS) live to around 13 to 15 years of age. The condition is extremely rare, with only about 152 children and young adults currently identified worldwide as of mid-2025. While there is no cure, a medication approved in 2020 has extended survival by roughly 2.5 years in treated patients.
What Progeria Does to the Body
Progeria is a genetic condition that causes dramatically accelerated aging in children. Babies with HGPS appear healthy at birth but begin showing signs of rapid aging within their first one to two years. The earliest changes include slowed growth, loss of body fat, hair loss, and wrinkled skin. Joints stiffen and lose range of motion early on.
The underlying cause is a mutation in a gene that produces a structural protein found in the nucleus of every cell. In progeria, the mutation creates an abnormal, shortened version of this protein, sometimes called progerin. Normally, the cell would trim a small chemical tag off this protein after it’s made. But progerin keeps that tag permanently attached, which disrupts the structure of cells throughout the body. This isn’t a case of something simply being missing. The defective protein actively interferes with normal cell function, driving the aging process forward at an extraordinary pace.
How Symptoms Progress Over Time
Within the first two years, the visible signs are already striking: children develop a characteristic appearance with a small face relative to the head, prominent eyes, and thin, wrinkled skin. Growth failure becomes obvious early, and most children with progeria remain very short and light for their age throughout life.
As children move through their first decade, the cardiovascular system bears the heaviest burden. Their blood vessels develop the same kind of plaque buildup and stiffening that typically takes decades to develop in the general population. By their early teens, most children with progeria have significant heart and blood vessel disease. Heart attacks and strokes are the primary cause of death, usually occurring in the mid-teens.
Notably, cognitive development is not affected. Children with progeria have normal intelligence and emotional development, which makes the physical progression especially difficult for families.
What Treatment Can Do
In 2020, the FDA approved a drug called Zokinvy (lonafarnib), the first treatment specifically for progeria. It works by blocking the chemical tag that stays stuck on the defective protein, reducing some of the cellular damage. With up to 11 years of follow-up data, treated patients lived an average of 2.5 years longer than untreated patients.
That gain is meaningful but modest. It does not stop the disease. Children on treatment still experience progressive cardiovascular damage and the other hallmarks of the condition. Researchers are now pursuing more ambitious approaches, including RNA-based therapies and gene editing. Studies in mice with progeria have shown dramatic improvements in lifespan using these genetic techniques, and the Progeria Research Foundation has completed an initial feasibility study in patients to test delivery methods for RNA therapy. A full clinical trial has not yet begun, but the groundwork is actively being laid.
Rare Exceptions to the Typical Lifespan
While the vast majority of people with HGPS die in their teens, there are rare outliers. Tiffany Wedekind of Columbus, Ohio, was 45 years old as of 2023, making her the oldest known progeria survivor. Her case is unusual in several ways. She went undiagnosed for years because she never developed the severe cardiovascular problems that define the condition for most patients. Her only notable symptom was her teeth falling out. Researchers believe her form of progeria differs slightly at the molecular level, which may explain her dramatically longer survival.
Cases like Wedekind’s are important for research but not representative. For the 152 children and young adults currently living with classic HGPS worldwide, the expected lifespan remains in the mid-teens, potentially extending into the late teens with treatment.